Skip to main content
Premium Trial:

Request an Annual Quote

Solexa Shuffles Board; Rosetta Genomics Names New Development VP; Sequenom Adds a Director

NEW YORK (GenomeWeb News) – Solexa this week said Douglas Fambrough has resigned as a director after a “special telephonic meeting of the board” held on Aug 28.
 
The company also said it has appointed to the board A. Blaine Bowman and Roy Whitfield. Both will serve on the audit committee, where Fambrough had served since early August.
 
Whitfield will also serve on the compensation committee. Additionally, Stephen Allen resigned from the audit committee.
 
Bowman, 60, was formerly chairman, president, and CEO of Dionex, where he is now a director. Whitfield, 52, was co-founder and former CEO of Ibncyte.

 
Peter Tolias has joined Rosetta Genomics as vice president of corporate development and head of US operations, he told GenomeWeb News this week. In January he stepped down as vice president at Ortho-Clinical Diagnostics and had said he would be taking time off before starting his next position, which he had not disclosed at the time.
 
Prior to Ortho-Clinical, Tolias was a director at the Center for Applied Genomics at the Public Health Research Institute in New Jersey. He helped found the center in January 2000.

 
BioDelivery Sciences International director L. M. Stephenson has died following “an extended illness,” the company said this week. He was a BDSI director since 2001.

 
Brevity has appointed Bruce Scott and Jennifer Widom to its advisory board.
 
Scott is a co-founder of Oracle and is currently vice president of engineering at SenSage. Widom is a professor at Stanford University's computer science and electrical engineering departments.'s computer science and electrical engineering departments.

 
Sequenom has appointed Paul Hawran to its board effective Aug. 21. He will chair the company’s audit committee, Sequenom said.
 
Hawran is executive vice president and chief financial officer at Neurocrine Biosciences, which he joined in 1993.
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.